Cohort study of the impact of high-dose opioid analgesics on overdose mortality

Pain Medicine (United States)

Volumn 17, Issue 1, 2016, Pages 85-98

  Dasgupta, Nabarun ^a,b   Funk, Michele Jonsson ^a,b   Proescholdbell, Scott ^c   Hirsch, Annie ^d,e   Ribisl, Kurt M ^b   Marshall, Steve ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c North Carolina Division of Public Health   (United States)

^d CDC CSTE Applied Epidemiology Fellowship   (United States)

^e North Carolina Div of Public Health   (United States)

Author keywords

Big Data; Chronic Pain; Cloud Computing; Cohort Study; Dose Response; Epidemiology; Opioids; Overdose; Prescriptions; Risk Factors

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; COCAINE; CODEINE; CONTROLLED SUBSTANCE; DIAMORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYMORPHONE; PRESCRIPTION DRUG;

ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG FATALITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG MONITORING; DRUG OVERDOSE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PROSPECTIVE STUDY; TREATMENT DURATION; AGED; MIDDLE AGED; MORTALITY; OPIOID-RELATED DISORDERS; PAIN;

AGED; ANALGESICS, OPIOID; BENZODIAZEPINES; COHORT STUDIES; DRUG OVERDOSE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; OPIOID-RELATED DISORDERS; PAIN; PRESCRIPTION DRUGS; PROSPECTIVE STUDIES;

EID: 84940930142     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12907     Document Type: Article

References (66)

1. Kritikos P, Papadaki S. The history of the poppy and of opium and their expansion in antiquity in the eastern Mediterranean area. Bull Narcotics 1967;17–38.
2. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011;305:1346–7.
3. Alexander GC, Kruszewski SP, Webster DW. Rethinking opioid prescribing to protect patient safety and public health. JAMA [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] 2012;308(18):1865–6.
4. Dowell D, Kunins HV, Farley TA. Opioid analgesics– risky drugs, not risky patients. JAMA 2013;309 (21):2219–20.
5. United Nations. Report of the International Narcotics Control Board for 2011. International Narcotics Control Board, Vienna, 2012.
6. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309(7):657–9.
7. Dhalla IA, Mamdani MM, Gomes T, Juurlink DN. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Can Fam Physician 2011;57(3):e92–6.
8. Gomes T, Juurlink D, Moineddin R, et al. Geographical variation in opioid prescribing and opioid-related mortality in Ontario. Healthc Q 2011; 14:22–4.
9. Warner M, Chen LH, Makuc DM, Anderson RN, Minin˜ o AM. Drug poisoning deaths in the United States, 1980– 2008. NCHS Data Brief 2011;81 (December):1–7.
10. Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005– 2009. Pharmacoepidemiol Drug Safety 2013;22(4):438–42.
11. Seya MJ, Gelders SF, Achara OU, Milani B, Scholten WK. A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels. J Pain Palliat Care Pharmacother 2011;25(1):6–18.
12. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000;283(13):1710–4.
13. Dasgupta N, Kramer ED, Zalman MA, et al. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006;82(2):135–42.
14. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Safe 2006;15(9):618–27.
15. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006;31(6):506–11.
16. Modarai F, Mack K, Hicks P, et al. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend 2013;132(1–2):81–6. doi: 10.1016/j.drugalcdep.2013.01.006.
17. Porucznik CA, Johnson EM, Sauer B, Crook J, Rolfs RT. Studying adverse events related to prescription opioids: The utah experience. Pain Med 2011; 12. Suppl 2:S16–S25.
18. Johnson EM, Lanier WA, Merrill RM, et al. Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008– 2009. J Gen Intern Med. 2012;28 (4):522–9. doi: 10.1007/s11606-012-2225-z.
19. Sims SA, Snow LA, Porucznik CA. Surveillance of methadone-related adverse drug events using multiple public health data sources. J Biomed Inform. 2007;40(4):382–9.
20. Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: How physicians can help control it. J Clin Psychiatry. 2011;72(5):589–92. doi: 10.4088/JCP.10com06560.
21. Haroutiunian S, McNicol ED, Lipman AG. Methadone for chronic non-cancer pain in adults. Cochrane Database Syst Rev 2012;11:CD008025
22. Whittle SL, Richards BL, Husni E, Buchbinder R. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev 2011;11:CD003113.
23. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;1:CD006605.
24. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006;(1):CD004311.
25. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 2010;152(2):85–92.
26. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171(7):686–91.
27. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011;5(1):e13–22.
28. Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 2012;13 (1):87–95.
29. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011;305 (13):1315–21.
30. Coplan P, Wentworth C, Sessler NE, Downing J, Alexander L, Chilcoat H. Opioid analgesic dos strength as a predictor of overdose risk in the UK. International Conference on Pharmacoepidemiology and Therapeutic Risk Management; Montreal, Canada, 2013.
31. Liang Y, Turner BJ. Assessing risk for drug overdose in a national cohort: Role for both daily and total opioid dose? J Pain 2015;16 (4):318–25.
32. King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: A systematic review. Am J Public Health 2014;104 (8):e32–42.
33. Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med 2014;174 (5):796–801.
34. Fulton-Kehoe D, Sullivan MD, Turner JA, et al. Opioid poisonings in Washington State Medicaid: Trends, dosing, and guidelines. Med Care 2015;53 (8):679–85.
35. Institute of Medicine. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press; 2011.
36. Webster LR. Considering the risks of benzodiazepines and opioids together. Pain Med [Editorial] 2010;11(6):801–2.
37. Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012;125(1-2):8–18.
38. Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999- 2009. Drug Alcohol Depend 2013;131(3):263–70. doi: 10.1016/j.drugalcdep.2012.11.018.
39. Roberts JM, Brewer DD. Measures and tests of heaping in discrete quantitative distributions. J Appl Stat 2001;28:887–96.
40. Gudin J. Risk evaluation and mitigation strategies (REMS) for extended-release and long-acting opioid analgesics: Considerations for palliative care practice. J Pain Palliat Care Pharmacother 2012;26 (2):136–43.
41. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999– 2008. MMWR Morbidity Mortality Weekly Report. 2011;60 (43):1487–92.
42. King J, Holmes M. Shaping health workforce policy through data-driven analyses: The North Carolina health professions data system. North Carolina Med J 2008;69(2):139–41.
43. Granko RP, Poppe LB, Savage SW, Daniels R, Smith EA, Leese P. Method to determine allocation of clinical pharmacist resources. Am J Health- System Pharmacy: AJHP 2012;69(16):1398–404.
44. Centers for Disease Control and Prevention. Bridged-Race Population Estimates Data Files and Documentation. Hyattsville, MD: US Department of Health and Human Services; 2012; Available at: http://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm (accessed January 2012).
45. Hernan MA, Hernandez-Diaz S. Beyond the intention- to-treat in comparative effectiveness research. Clin Trials 2012;(1):48–55.
46. Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat Med 1991;10(3):457–62.
47. Hardin JW, Hilbe J. Generalized linear models and extensions, 2nd edition. College Station, TX: Stata Press; 2007.
48. Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton, FL: Chapman & Hall/CRC; 2003.
49. Rogers WH. Regression standard errors in clustered samples. Stata Techn Bull. 1993;13:19–23.
50. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2015;72 (2):136–42.
51. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: Case-cohort study. Bmj. 2015; 350:h2698
52. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women–United States, 1999- 2010. MMWR Morb Mortal Weekly Rep 2013; 62(26):537–42.
53. Carey TS, Freburger JK, Holmes GM, et al. Race, care seeking, and utilization for chronic back and neck pain: Population perspectives. J Pain: Off J Am Pain Soc 2010;11(4):343–50.
54. Meghani SH, Byun E, Gallagher RM. Time to take stock: A meta-analysis and systematic review of analgesic treatment disparities for pain in the United States. Pain Med 2012;13(2):150–74.
55. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: A review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician [Review]. 2012;15(3 Suppl):ES67–92.
56. Governale L. Outpatient Prescription Opioid Utilization in the U.S., Years 2000 – 2009. Food and Drug Administration; 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugs AdvisoryCommittee/UCM220950.pdf(accessed May 2013).
57. Svendsen K, Skurtveit S, Romundstad P, Borchgrevink PC, Fredheim OM. Differential patterns of opioid use: Defining persistent opioid use in a prescription database. Eur J Pain. 2012;16 (3):359–69.
58. Rhodes T. The ‘risk environment’: A framework for understanding and reducing drug-related harm. Int J Drug Policy 2002;13(2):85–94.
59. Rhodes T. Risk environments and drug harms: A social science for harm reduction approach. Int J Drug Policy 2009;20(3):193–201.
60. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010;376 (9737):268–84.
61. Albert S, Brason II FW, Sanford CK, Dasgupta N, Graham J, Lovette B. Project lazarus: Communitybased overdose prevention in rural North Carolina. Pain Med 2011; 12. Suppl 2:S77–85.
62. Cicero TJ, Ellis MS, Surratt HL. Effect of abusedeterrent formulation of OxyContin. N Engl J Med 2012;367(2):187–9.
63. Webster LR, Dasgupta N. Obtaining adequate data to determine causes of opioid-related overdose deaths. Pain Med 2011;12(S2):S86–S92.
64. Pounder DJ, Jones GR. Post-mortem drug redistribution–a toxicological nightmare. Forensic Sci Int. [Case Reports]. 1990;45(3):253–63.
65. Mort JR, Shiyanbola OO, Ndehi LN, Xu Y, Stacy JN. Opioid-paracetamol prescription patterns and liver dysfunction: A retrospective cohort study in a population served by a US health benefits organization. Drug Saf 2011;34(11):1079–88.
66. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med 2011; 12(S2):S26–S35.